Immix Biopharma, Inc.

corporate_fare Company Profile

Immix Biopharma, Inc.

IMMX·NASDAQ·Life Sciences·CIK 0001873835

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware on January 7, 2014. The company focuses on developing cell therapies for AL Amyloidosis and specific immune-mediated diseases. In August 2016, Immix Biopharma established a wholly-owned Australian subsidiary, Immix Biopharma Australia Pty Ltd. (IBAPL), to conduct preclinical and clinical activities for its development candidates. In November 2022, the company formed Nexcella, Inc., a majority-owned subsidiary and its cell therapy division. Nexcella subsequently merged into Immix Biopharma, Inc. in May 2024, with Immix Biopharma, Inc. continuing as the surviving entity. The company's fiscal year ends on December 31.

Immix Biopharma, Inc. (NASDAQ:IMMX) is a publicly traded company in the Life Sciences sector. Wiseek monitors IMMX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

$150M Stock Offering Closes for Immix Biopharma, Bolstering Funds After Strong NXC-201 Trial Results (2026-05-22)
Immix Biopharma Secures Funding to Mid-2028, Targets March 2027 for Key NXC-201 Data (2026-05-22)
Immix Biopharma Prices $150M Public Offering at Premium Following Positive Clinical Data (2026-05-21)
Immix Biopharma Prices $150M Public Offering at Market Price Following Strong Clinical Data (2026-05-21)
Immix Biopharma Prices $150M Underwritten Offering at 10.5% Discount, Extending Runway to Mid-2028 (2026-05-21)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$29.44M

Diluted EPS

-$0.89

Op. Cash Flow

-$23.93M

Free Cash Flow

-$24.66M

Operating Income

-$29.96M

Cash & Equivalents

$93.93M

Debt / Equity

0.00×

Shares Outstanding

52.95M sh

Source: 10-K · filed 2026-03-27 · accession 0001493152-26-013298

Browse all tickers starting with I →

show_chartPrice Chart

Loading chart...

feed IMMX - Latest Insights

Filing Type

Date Range

IMMX

May 22, 2026, 5:15 PM EDT

Source: GlobeNewswire

Importance Score:

$150M Stock Offering Closes for Immix Biopharma, Bolstering Funds After Strong NXC-201 Trial Results

Price at Filing: $8.75

Real-time Price: $8.45

Change: -$0.300 (-3%)

Market Cap: $601.555M

Sentiment: Positive

View Wiseek Article

IMMX

May 22, 2026, 3:15 AM EDT

Source: Wiseek News

Importance Score:

Immix Biopharma Secures Funding to Mid-2028, Targets March 2027 for Key NXC-201 Data

Price at Filing: $8.67

Real-time Price: $8.45

Change: -$0.220 (-3%)

Market Cap: $601.555M

Sentiment: Positive

View Wiseek Article

IMMX

May 21, 2026, 5:28 PM EDT

Filing Type: 8-K

Importance Score:

Immix Biopharma Prices $150M Public Offering at Premium Following Positive Clinical Data

Price at Filing: $8.67

Real-time Price: $8.45

Change: -$0.220 (-3%)

Market Cap: $601.555M

Sentiment: Positive

View Wiseek Article

IMMX

May 21, 2026, 5:24 PM EDT

Filing Type: 424B5

Importance Score:

Immix Biopharma Prices $150M Public Offering at Market Price Following Strong Clinical Data

Price at Filing: $8.67

Real-time Price: $8.45

Change: -$0.220 (-3%)

Market Cap: $601.555M

Sentiment: Positive

View Wiseek Article

IMMX

May 21, 2026, 6:38 AM EDT

Filing Type: FWP

Importance Score:

Immix Biopharma Prices $150M Underwritten Offering at 10.5% Discount, Extending Runway to Mid-2028

Price at Filing: $9.99

Real-time Price: $8.45

Change: -$1.54 (-15%)

Market Cap: $601.555M

Sentiment: Negative

View Wiseek Article

IMMX

May 21, 2026, 6:33 AM EDT

Source: Reuters

Importance Score:

Immix Biopharma Prices $150M Stock Offering, Diluting Shares by Over 30%

Price at Filing: $9.54

Real-time Price: $8.45

Change: -$1.09 (-11%)

Market Cap: $601.555M

Sentiment: Negative

View Wiseek Article

IMMX

May 21, 2026, 6:04 AM EDT

Filing Type: 8-K

Importance Score:

Immix Biopharma Reports 95% Complete Response Rate in NEXICART-2 AL Amyloidosis Trial

Price at Filing: $9.50

Real-time Price: $8.45

Change: -$1.05 (-11%)

Market Cap: $601.555M

Sentiment: Positive

View Wiseek Article

IMMX

May 21, 2026, 6:00 AM EDT

Source: GlobeNewswire

Importance Score:

Immix Biopharma's NXC-201 Achieves 95% Complete Response Rate in Pivotal AL Amyloidosis Trial

Price at Filing: $9.50

Real-time Price: $8.45

Change: -$1.05 (-11%)

Market Cap: $601.555M

Sentiment: Positive

View Wiseek Article

IMMX

May 07, 2026, 5:17 PM EDT

Filing Type: 10-Q

Importance Score:

Immix Biopharma Reports Increased Quarterly Loss, Secures $17.1M in Post-Quarter ATM Sales to Extend Runway

Price at Filing: $9.73

Real-time Price: $8.45

Change: -$1.28 (-13%)

Market Cap: $601.555M

Sentiment: Neutral

View Wiseek Article

IMMX

Mar 30, 2026, 8:45 AM EDT

Source: GlobeNewswire

Importance Score:

Immix Biopharma Completes Enrollment for BLA-Enabling AL Amyloidosis Trial NEXICART-2; Topline Results Expected Q3 2026

Price at Filing: $8.60

Real-time Price: $8.45

Change: -$0.150 (-2%)

Market Cap: $601.555M

Sentiment: Positive

View Wiseek Article

IMMX

Mar 25, 2026, 5:25 PM EDT

Source: Wiseek News

Importance Score:

Immix Biopharma Posts $29.44M Net Loss, $(0.89) EPS in 2025 10-K

Price at Filing: $9.05

Real-time Price: $8.45

Change: -$0.600 (-7%)

Market Cap: $601.555M

Sentiment: Negative

View Wiseek Article

IMMX

Mar 25, 2026, 5:23 PM EDT

Filing Type: 8-K

Importance Score:

Immix Biopharma Amends ATM Program, Increasing Potential Offering to $100 Million

Price at Filing: $9.05

Real-time Price: $8.45

Change: -$0.600 (-7%)

Market Cap: $601.555M

Sentiment: Negative

View Wiseek Article

IMMX

Mar 25, 2026, 5:21 PM EDT

Filing Type: 424B5

Importance Score:

Immix Biopharma Details $100M ATM Offering, Discloses Initial $4.4M in Sales

Price at Filing: $9.05

Real-time Price: $8.45

Change: -$0.600 (-7%)

Market Cap: $601.555M

Sentiment: Neutral

View Wiseek Article

IMMX

Mar 25, 2026, 5:19 PM EDT

Filing Type: 10-K

Importance Score:

Immix Biopharma Secures Breakthrough Therapy Designation for NXC-201, Reports Strong Phase 2 Data & $113M+ in 2025 Financing

Price at Filing: $9.05

Real-time Price: $8.45

Change: -$0.600 (-7%)

Market Cap: $601.555M

Sentiment: Neutral

View Wiseek Article

IMMX

Jan 09, 2026, 5:28 PM EST

Filing Type: S-3

Importance Score:

Immix Biopharma Files $750M Shelf Registration, Signaling Substantial Future Dilution

Price at Filing: $4.78

Real-time Price: $8.45

Change: +$3.67 (+77%)

Market Cap: $601.555M

Sentiment: Negative

View Wiseek Article

corporate_fare Company Profile